logo
Cellugy Raises 8.1 Million Euros to Eliminate Microplastics in Personal Care Products

Cellugy Raises 8.1 Million Euros to Eliminate Microplastics in Personal Care Products

Yahoo6 hours ago

PARIS — Danish biotech company Cellugy has raised 8.1 million euros from the European Union to eliminate microplastics in personal care products and to use a bio-based alternative instead.
Cellugy's Biocare4life project received the grant from the Life program, an EU funding branch supporting projects backing environmental and climate action. The raise is to accelerate the production scale-up toward commercializing Cellugy's biofabricated material platform, called EcoFlexy.
More from WWD
Fragrance Dupe Brand Dossier Is Opening Stores
Paris Good Fashion Report Says 20% Volume Cut Needed by 2030 to Stay Within Climate Limits
From Flooding to Heat Stress, Climate Challenges Are Threatening the Shoe Industry Like Never Before
EcoFlexy Rheo is the platform's debut product. It's the first high-performance rheology modifier that's totally bio-based, biodegradable and competitively priced, according to Cellugy, which is based in Søborg, Denmark. That is meant to give the personal care industry a good alternative to microplastics and fossil-based ingredients that are widely used.
'EcoFlexy is designed to replace fossil-based carbomers, known as harmful microplastics, significantly reducing environmental pollution and the use of hazardous chemicals in the cosmetics sector,' Cellugy said in a statement.
'It delivers superior product performance and adaptable sensorial properties, along with scalable, operationally efficient manufacturing to meet the needs of a fast-evolving beauty industry focused on sustainability and innovation,' the company continued.
Many personal care products, such as facial scrubs and liquid soaps, can release microplastics, adding to environmental pollution.
'Recent research also suggests that microplastics can enter the human body through inhalation, ingestion or skin contact, raising questions about their potential impacts on human health,' Cellugy said.
It explained rheology modifiers are essential to all personal care products, but that almost 70 percent of the 2.8-billion-euro rheology modifier market is dependent on fossil-based carbomers and acrylates, which are listed under the EU's Reach regulation because of their persistent and toxic nature, Cellugy said.
'Through the Biocare4life project, EcoFlexy is positioned to prevent the release of 259 tons of microplastics annually by project completion, scaling dramatically to 1,289 tons per year by 2034, equivalent to removing millions of contaminated beauty products from the market each year,' Cellugy said.
The company said the timing is key as reports suggest the beauty industry might lose around 12 billion euros because of the EU microplastic ban and U.S. restrictions on PFAS, or 'forever chemicals.'
Challenges abound.
'An alternative material that simply aims to be more sustainable is not enough. The critical challenge is about delivering bio-based solutions that actually outperform petrochemicals in performance parameters like texture, functionality and user experience, while also being scalable and operationally efficient,' said Isabel Alvarez-Martos, chief executive officer and cofounder of Cellugy, in the statement.
'Good intentions won't drive industry change. We need higher-quality alternatives like EcoFlexy that make it easier, not harder, for brands to choose sustainability,' she continued. 'Only when bio-based materials match or exceed the performance and economics of traditional ingredients will we see the transformation needed to protect both human health and our planet.'
The Biocare4life project is to drive EcoFlexy's scale-up process via the work of a specialist consortium of experts in biotech, sustainability and data management. These include The Footprint Firm, a consultancy focused on circular economy solutions and environmental impact validation, and Sci2sci, a start-up focused on data management, machine learning and AI-driven process optimization.
'The project signals real progress toward more sustainable manufacturing in the personal care sector,' said Will Nunn, manager at The Footprint Firm. 'The project's combination of technical innovation and sustainability validation positions EcoFlexy very strongly for market adoption and supports the EU's broader transition to a more resource-efficient economy.'
'Scaling a biotech solution is never simple, but it's where the real value lies,' continued Angelina Lesnikova, Sci2sci CEO. 'Together, we have the potential to make sustainable chemistry economically irresistible as well as environmentally essential.'
The funding is expected to back Cellugy's scaling activities, process optimization and commercial validation over four years.
Best of WWD
Which Celebrity Brands Are Next for a Major Deal? Lady Gaga, Beyonce and More Possible Contenders for the Next Corporate Prize
The Best Makeup Looks in Golden Globes History
A Look Back at Golden Globes Best Makeup on the Red Carpet, From Megan Fox to Sophia Loren [PHOTOS]

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tesla's European sales slump for fifth month as EV rivals gain momentum
Tesla's European sales slump for fifth month as EV rivals gain momentum

Yahoo

timean hour ago

  • Yahoo

Tesla's European sales slump for fifth month as EV rivals gain momentum

By Jesus Calero (Reuters) -Tesla's new car sales in Europe fell 27.9% in May from a year earlier even as fully-electric vehicle sales in the region jumped 27.2%, with the U.S. EV maker's revised Model Y yet to show signs of reviving the brand's fortunes. Overall car sales in Europe rose 1.9%, with the strongest growth coming from plug-in hybrids and cars powered by alternative fuels, data from the European Automobile Manufacturers Association (ACEA) showed. WHY IT'S IMPORTANT Tesla's European sales have now fallen for five straight months as customers switch to cheaper Chinese EVs and, in some cases, protest against Tesla CEO Elon Musk's politics. Tesla's European market share dropped to just 1.2% in May from 1.8% a year ago. The revised Model Y is meant to revamp the company's ageing model range as traditional automakers and Chinese rivals launch EVs at a rapid pace amid trade tensions. BY THE NUMBERS May new car sales in the European Union, Britain and the European Free Trade Association rose to 1.11 million vehicles, following a 0.3% dip in April, ACEA data showed. Registrations at Chinese state-owned SAIC Motor and Germany's BMW rose 22.5% and 5.6% respectively, while they fell 23% at Japan's Mazda. In the EU alone, total car sales have fallen 0.6% so far this year. That comes despite growing demand for EVs, with registrations of battery-electric (BEV), plug-in hybrid (PHEV) and hybrid-electric (HEV) cars rising 26.1%, 15% and 19.8% respectively. EU sales of BEVs, HEVs and PHEVs combined accounted for 58.9% of passenger car registrations in May, up from 48.9% in May 2024. Among the largest EU markets, new car sales in Spain and Germany rose 18.6% and 1.2% respectively, while in France and Italy they dropped by 12.3% and 0.1%. In Britain, registrations were up 1.6%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

EuroPA and EPI collaborate to strengthen cross-border payments in Europe
EuroPA and EPI collaborate to strengthen cross-border payments in Europe

Yahoo

timean hour ago

  • Yahoo

EuroPA and EPI collaborate to strengthen cross-border payments in Europe

The EuroPA alliance and EPI Company have collaborated to explore solutions for enhancing Europe's sovereignty in payments, focusing on cross-border transactions. The initiative aims to allow European citizens to send and receive payments seamlessly across the continent, supporting both consumers and merchants. EuroPA alliance includes Bancomat, Bizum, MB WAY (SIBS), and Vipps MobilePay. 'The collaboration between EuroPA and EPI is driven by a shared interest in exploring a joint solution that leverages the strong adoption and existing capabilities of each participant through enhanced interconnectivity,' EPI said in a press release. The partnership seeks to cover all payment types, including person-to-person and commercial transactions, both online and in-store, across participating markets. A study to assess the collaboration's potential is underway and is expected to conclude by the end of summer 2025. The agreement will initially span 15 European countries. Users will be able to use their preferred digital payment solutions locally and across Europe, with provisions for markets lacking such systems. Interconnecting existing payment solutions is viewed as a quick way to achieve European sovereignty in payments, a goal shared by the European Commission and Eurosystem. EuroPA, the European Payments Alliance, unites major mobile payment providers in their markets. It focuses on creating a strong pan-European payments market through interoperability, using SEPA instant payment standards. Since March 2025, Bancomat, Bizum, and MB WAY/SIBS have enabled over 50 million users in Andorra, Italy, Portugal, and Spain—backed by 186 financial institutions—to transfer money instantly. New members Blik (Poland), IRIS (Greece), and Vipps MobilePay (Nordic countries) have joined, with integration planned, expanding EuroPA to over 100 million users in 10 countries. EPI, the European Payments Initiative, is supported by 16 European banks and payment providers. It aims to offer Wero, a unified mobile payment service, for retail transactions via a European digital wallet. "EuroPA and EPI collaborate to strengthen cross-border payments in Europe" was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks
Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks

Business Insider

time2 hours ago

  • Business Insider

Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks

On Monday, Hims & Hers (HIMS) stock plunged about 35% after Danish drugmaker Novo Nordisk (NVO) ended its partnership with HIMS, accusing it of illegally selling copycats of its weight-loss drug Wegovy (semaglutide). In reaction, Needham analyst Ryan MacDonald downgraded Hims & Hers stock to Hold from Buy and removed the $65 price target. Needham also removed HIMS stock from its Conviction List. Other Wall Street analysts also weighed in on HIMS' fallout with Novo Nordisk, noting legal risks. Confident Investing Starts Here: Needham Downgrades HIMS Stock to Hold MacDonald downgraded HIMS stock due to the termination of the key deal with Novo Nordisk and fears of a potential lawsuit. The 4-star analyst thinks that Hims & Hers will likely continue to offer personalized GLP-1s (drugs for weight loss and diabetes) under its interpretation of section 503A (outlines the conditions under which compounded drug products are exempt from certain FDA requirements). This, he believes, brings back the risk of litigation or regulatory action. He added that HIMS is now at a competitive disadvantage, given that both Eli Lilly (LLY) and Novo Nordisk maintain partnerships with its rivals. MacDonald believes that HIMS stock could be range-bound over the near term, as the legality of HIMS' personalization practices is determined. Other Analysts Weigh in on HIMS-NOVO Fallout Meanwhile, Morgan Stanley analyst Craig Hettenbach reiterated a Hold rating on Hims & Hers stock with a price target of $40. Hettenbach estimates that 'personalized' compounded semaglutide doses comprise over 50% of HIMS' target of $725 million in weight loss revenue for 2025. The 4-star analyst thinks that the abrupt termination of the deal could renew concerns over litigation. Further, Truist Securities analyst Jailendra Singh reiterated a Hold rating on HIMS stock with a price target of $45. Singh also believes that with the termination of the partnership, the litigation risk is 'back on the table.' He added that a potential litigation could drag on for 18-24 months and remain an overhang on HIMS stock. That said, Singh does not believe that branded Wegovy was driving any significant subscriber growth or revenue for HIMS, likely resulting in Novo's decision to end the collaboration. However, Singh thinks that HIMS was perhaps gaining from the 'credibility' or increased consumer traffic to its platforms due to ads for the branded Wegovy. Consequently, Singh expects the end of the deal to trigger a decline in traffic, adversely impacting HIMS' compounding business. Finally, Bank of America analyst Allen Lutz reiterated a Sell rating on Hims & Hers stock with a price target of $28, saying that the end of the deal was a 'clear negative.' Lutz sees a high likelihood of Novo Nordisk pursuing litigation. The 4-star analyst noted that HIMS generated $230 million of compounded semaglutide revenue in Q1 2025 and is expected to deliver about $170 million in Q2. He estimates that Wegovy represented a low single-digit percentage of GLP-1s (~2%) orders in Q2, implying that the loss of the partnership won't result in any notable change to revenue. That said, Lutz noted a slowdown in HIMS' core business, which presents a significant risk to consensus estimates in the second half of 2025 and 2026. Blame Game On Novo Nordisk blamed Hims & Hers for 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy,' putting patient safety at risk. Meanwhile, responding to the termination of the deal, Hims & Hers CEO Andrew Dudum stated that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum accused Novo Nordisk's commercial team of increasing pressure on Hims & Hers to control clinical standards and move patients to Wegovy regardless of whether it was clinically best for patients. He added that HIMS refuses to be 'strong-armed' by any anticompetitive demand of any pharmaceutical company that impacts the independent decision-making of providers and limits patient choice. Is HIMS a Good Stock to Buy? Overall, Wall Street is sidelined on HIMS stock, with a Hold consensus rating based on one Buy, eight Holds, and two Sell recommendations. The average HIMS stock price target of $39.80 indicates about 5.2% upside potential.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store